Table 5.
Vaccination coverage for seasonal influenza, tetanus, pneumococcal disease, herpes zoster and COVID-19, per age group and sex.
| Age Group | Influenza n (%) |
Tetanus n (%) |
Pneumococcal Disease n (%) |
Herpes Zoster n (%) |
COVID-19 1 Dose * n (%) |
COVID-19 2 Doses ** n (%) |
COVID-19 ≥3 Doses *** n (%) |
|---|---|---|---|---|---|---|---|
| All age groups | |||||||
| Total | 189/394 (48%) |
130/393 (33.1%) |
105/394 (26.6%) |
33/395 (8.3%) |
7/394 (1.8%) |
45/394 (11.4%) |
295/394 (74.8%) |
| Men | 85/164 (51.8%) |
73/163 (44.8%) |
52/163 (31.9%) |
17/164 (10.4%) |
3/164 (1.8%) |
14/164 (8.5%) |
134/164 (81.7%) |
| Women | 104/230 (45.2%) |
57/230 (24.8%) |
53/231 (22.9%) |
16/231 (6.9%) |
4/230 (1.7%) |
31/230 (13.5%) |
161/230 (70%) |
| 18–29 years old | |||||||
| Total | 7/47 (14.9%) |
26/47 (55.3%) |
3/47 (6.4%) |
- | 1/46 (2.2%) |
14/46 (30.4%) |
19/46 (41.3%) |
| Men | 1/17 (5.9%) |
14/17 (82.3%) |
0/17 (0%) |
- | 0/17 (0%) |
4/17 (23.5%) |
10/17 (58.8%) |
| Women | 6/30 (20%) |
12/30 (40%) |
3/30 (10%) |
- | 1/29 (3.4%) |
10/29 (34.5%) |
9/29 (31%) |
| 30–39 years old | |||||||
| Total | 12/59 (20.3%) |
17/59 (28.8%) |
5/59 (8.5%) |
- | 1/59 (1.7%) |
6/59 (10.2%) |
45/59 (76.3%) |
| Men | 3/16 (27.1%) |
9/16 (56.2%) |
2/16 (12.5%) |
- | 1/16 (6.2%) |
0/16 (0%) |
15/16 (93.7%) |
| Women | 9/43 (20.9%) |
8/43 (18.6%) |
3/43 (6.7%) |
- | 0/43 (0%) |
6/43 (14%) |
30/43 (69.8%) |
| 40–49 years old | |||||||
| Total | 29/71 (40.85%) |
26/70 (37.1%) |
9/71 (12.7%) |
- | 4/72 (5.6%) |
11/72 (15.3%) |
50/72 (69.4%) |
| Men | 10/26 (38.5%) |
9/25 (36%) |
5/25 (20%) |
- | 2/26 (7.7%) |
3/26 (11.5%) |
18/26 (69.2%) |
| Women | 19/45 (42.2%) |
17/45 (37.8%) |
4/46 (8.7%) |
- | 2/46 (4.3%) |
8/46 (17.4%) |
32/46 (69.6%) |
| 50–59 years old | |||||||
| Total | 41/89 (46%) |
26/89 (29.2%) |
18/89 (20.2%) |
- | 0/89 (0%) |
9/89 (10.1%) |
65/89 (73%) |
| Men | 15/32 (46.9%) |
13/32 (40.6%) |
6/32 (18.7%) |
- | 0/32 (0%) |
2/32 (6.3%) |
24/32 (75%) |
| Women | 26/57 (45.6%) |
13/57 (22.8%) |
12/57 (21%) |
- | 0/57 (0%) |
7/57 (12.3%) |
41/57 (71.9%) |
| 60–64 years old | |||||||
| Total | 28/44 (63.6%) |
15/44 (34.1%) |
16/44 (36.4%) |
8/44 (18.2%) |
0/44 (0%) |
1/44 (2.3%) |
41/44 (93.2%) |
| Men | 11/21 (52.4%) |
10/21 (47.6%) |
7/21 (33.3%) |
3/21 (14.3%) |
0/21 (0%) |
1/21 (4.8%) |
20/21 (95.2%) |
| Women | 17/23 (73.9%) |
5/23 (21.7%) |
9/23 (39.1%) |
5/23 (21.7%) |
0/23 (0%) |
0/23 (0%) |
21/23 (91.3%) |
| 65+ years old | |||||||
| Total | 72/84 (85.7%) |
20/84 (23.8%) |
54/84 (64.3%) |
25/84 (29.8%) |
1/84 (1.2%) |
4/84 (4.8%) |
75/84 (89.3%) |
| Men | 45/52 (86.5%) |
18/52 (34.6%) |
32/52 (61.5%) |
14/52 (26.9%) |
0/52 (0%) |
4/52 (7.7%) |
47/52 (90.4%) |
| Women | 27/32 (84.4%) | 2/32 (6.2%) |
22/32 (68.7%) |
11/32 (34.4%) | 1/32 (3.1%) |
0/32 (0%) |
28/32 (87.5%) |
* 1 dose indicates partial/incomplete vaccination; ** 2 doses indicate complete primary COVID-19 vaccination; *** ≥3 doses indicate booster shots.